BCL2 Family Related Genes Expression and Chemotherapy Response in Diffuse Large B-Cell Lymphoma

Authors

  • Abdolazim Sedighi Pashaki Dept. of Radiotherapy Oncology and Cancer Research Center, Mashhad Univiversity of Medical Sciences, Mashhad, Iran.
  • Hamid Reza Raziee Dept. of Radiotherapy Oncology and Cancer Research Center, Mashhad Univiversity of Medical Sciences, Mashhad, Iran.
  • Kazem Anvari Dept. of Radiotherapy Oncology and Cancer Research Center, Mashhad Univiversity of Medical Sciences, Mashhad, Iran.
  • Mahmoud Reza Kalantari Dept. of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran
  • Mehdi Seilanian Toosi Dept. of Radiotherapy Oncology and Cancer Research Center, Mashhad Univiversity of Medical Sciences, Mashhad, Iran.
  • Mohammad Reza Ghavam Nasiri Dept. of Radiotherapy Oncology and Cancer Research Center, Mashhad Univiversity of Medical Sciences, Mashhad, Iran.
Abstract:

  Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens were stained with immunohistochemistery method for Bax and Bcl2. The relationship between Bax/Bcl2 expression and the response to chemotherapy as well as some other prognostic factors were assessed. Results: Out of 44 patients, 29 were Bax+ and 15 Bax-, 31 Bcl2+ and 13 Bcl2-. We found a statistically significant relationship between IPI score and the response to chemotherapy (P = 0.002).  The response rates were relatively better (but not significant) in cases with Bax + compared to Bax – and in patients with Bcl2- compared to Bcl2 + tumors. The combination of  immunohistochemistery results for Bcl2 and Bax could predict relatively higher response rates in a way that those with Bax+ Bcl2- had a higher response compared to Bax- Bcl2+ ( 57%% VS.22%, p=0.15). Conclusion:  Although we found a relatively higher responses in our cases with Bax + vs. Bax - and in those with Bcl2- vs. Bcl2 +, the differences were not statistically significant. We suggest further studies to confirm whether the Bcl2 and Bax expressions have any effect on the response to chemotherapy and whether they could be considered as predictor factors for chemotherapy response.   

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

bcl2 family related genes expression and chemotherapy response in diffuse large b-cell lymphoma

background and objective: approximately half of patients with diffuse large b-cell lymphoma are cured with current chemotherapy regimens. the purpose of this study was to evaluate bax and bcl2 expression and their relationship with the response to chemotherapy. materials and methods this study was a prospective analysis on 44 patients with diffuse large b-cell lymphoma. their specimens were sta...

full text

A Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?

Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...

full text

HISTIOCYTE-RICH B-CELL LYMPHOMA: A CASE REPORT OF A RARE VARIANT OF DIFFUSE LARGE B-CELL LYMPHOMA

The authors describe a case of histiocyte-rich B-cell lymphoma (HR-BCL), a variant of diffuse large B-cell lymphoma, in a 51-year-old man. The patient presented with large axillary lymphadenopathy. Histopathologic and immunohistochemical examination of lymph node biopsy revealed diffuse effacement of the lymph node architecture by reactive histiocytes and neoplastic CD20 positive B cells. ...

full text

A Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?

Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...

full text

Primary Hepatic Diffuse Large B-Cell Lymphoma in a Patient with Scleroderma

  Primary Hepatic Lymphoma (PHL) is rare and possibly associated with viral hepatitis and autoimmune diseases. Scleroderma could exceptionally be complicated by lymphoma. We describe PHL occurring in a 52-year-old female suffering scleroderma for eight years, with no history of cytotoxic or high-dose glucocorticoid therapy. CT scan, performed to work-up abdominal discomfort, constipation, and ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 1

pages  32- 37

publication date 2009-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023